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Abstract
Problem/Condition: Lead is neurotoxic and particularly harmful to the developing nervous systems of fetuses and young
children. Extremely high blood lead levels (BLLs) (i.e., >70 µg/dL) can cause severe neurologic problems (e.g., seizure,
coma, and death). However, no threshold has been determined regarding lead’s harmful effects on children’s learning and
behavior. In 1990, the U.S. Department of Health and Human Services established a national goal to eliminate BLLs >25
µg/dL by 2000; a new goal targets elimination of BLLs >10 µg/dL in children aged <6 years by 2010.
Reporting Period: Information regarding children’s BLLs comes from 1) National Health and Nutrition Examination
Surveys (NHANES) conducted during 1976–1980, 1988–1991, 1991–1994, and 1999–2000; and 2) state child blood
lead surveillance data for test results collected during 1997–2001.
Description of System: CDC tracks children’s BLLs in the United States by using both NHANES and state and local
surveillance data. NHANES reports data regarding children aged 1–5 years; state and local surveillance systems report
data regarding children aged <72 months. Because lead exposure in children varies among populations and communi-
ties, both surveys are needed to determine the burden of elevated BLLs among young children throughout the United
States. NHANES uses highly standardized data-collection procedures and probability samples to gather information
regarding the health and nutritional status of the civilian, noninstitutionalized U.S. population. State and local child-
hood lead surveillance systems are based on reports of blood lead tests from laboratories. State and local programs
submit data to CDC annually. In this report, confirmed elevated BLLs are defined as one venous blood specimen >10
µg/dL or two capillary blood specimens >10 µg/dL drawn within 12 weeks of each other.
Results: The NHANES 1999–2000 survey estimated that 434,000 children (95% confidence interval = 189,000–846,000)
or 2.2% of children aged 1–5 years had BLLs >10 µg/dL. For 2001, a total of 44 states, the District of Columbia (DC),
and New York City (NYC) submitted child blood lead surveillance data to CDC. These jurisdictions represent 95% of
the U.S. population of children aged <72 months and 97% of the nation’s pre-1950 housing. The number of children
tested and reported to CDC increased from 1,703,356 in 1997 (37 states, DC, and NYC reporting), to 2,422,298 in
2001 (44 states, DC, and NYC reporting). During that time, the number of children reported with confirmed elevated
BLLs >10 µg/dL steadily decreased from 130,512 in 1997 to 74,887 in 2001. In 2000, the year targeted for national
elimination of BLLs >25 µg/dL, a total of 8,723 children had BLLs >25 µg/dL.
Interpretation: Both national surveys and state surveillance data indicate children’s BLLs continue to decline through-
out the United States. However, thousands of children continue to be identified with elevated BLLs. The 2000 goal of
eliminating BLLs >25 µg/dL was not met. Attaining the 2010 goal of eliminating BLLs >10 µg/dL will require intensi-
fied efforts to target areas at highest risk, evaluate preventive measures, and improve the quality of surveillance data.
Public Health Actions: States will continue to use surveillance data to 1) promote legislation supporting lead poison-
ing prevention activities, 2) obtain funding, 3) identify risk groups, 4) target and evaluate prevention activities, and 5)
monitor and describe progress toward elimination of BLLs >10 µg/dL. CDC will work with state and local programs to
improve tracking systems and the collection, timeliness, and quality of surveillance data.
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Introduction
Exposure to lead can damage the nervous, hematopoietic,
and renal systems (1,2) and is particularly harmful to the
developing nervous systems of fetuses and children aged <72
months. Extremely elevated blood lead levels (BLLs) >70 µg/
dL can cause severe neurologic problems (e.g., seizure, coma,
and death) (3). Although severe cases are rare today (4), the
threshold for harmful effects of lead remains unknown. Since
1975, as new data became available, CDC has revised its rec-
ommendations regarding the threshold of BLLs that should
raise concern and trigger interventions (5–7). By 1991, CDC
had lowered the BLL threshold 66.6% to 10 µg/dL, from 30
µg/dL in 1975 (5,7), in response to studies in the late 1980s
that linked BLLs as low as 10 µg/dL with decreased intelli-
gence and other adverse neurodevelopmental effects (8–11).
Ongoing research conducted since 1991 provides evidence of
adverse effects at even lower levels, <10 µg/dL, among chil-
dren aged <72 months (12–16).
The principal sources of lead exposure for children in the
United States are house dust contaminated by leaded paint
and soil contaminated by both leaded paint and decades of
industrial and motor vehicle emissions (1). Lead was widely
used in paint through the 1940s. Although lead use declined
during the 1950s and 1960s (17), and lead was banned from
residential use in 1978*, lead remains a hazard in homes built
before the ban, especially in pre-1950 housing. During 1991–
1994, CDC’s National Health and Nutrition Examination
Survey (NHANES) determined the prevalence of BLLs >10
µg/dL was highest among children living in pre-1946 homes
(8.6%), compared with children living in homes built during
1946–1973 (4.6%), and after 1973 (1.6%). Among children
living in pre-1946 housing, prevalence of BLLs >10 µg/dL
differed substantially by family income. Prevalence among
children from low-income families was 16.4%, compared with
4.1% and 0.9% among children from middle- and high-
income families (18).
National Elimination Goals
The U.S. Department of Health and Human Services
(DHHS) established a national goal to eliminate BLLs >25
µg/dL in children aged 6 months–5 years by 2000. This goal
was announced in September 1990 in Healthy People 2000
(19). The next year, the U.S. Public Health Service released
its Strategic Plan for the Elimination of Childhood Lead Poi-
soning (20). The plan called for a societywide effort to elimi-
nate lead poisoning as a public health problem by 2011. Lead
poisoning was defined as BLLs >25 µg/dL, but the plan noted
CDC was considering lowering that level. The plan called for
1) more childhood lead poisoning prevention programs and
activities; 2) effective abatement of leaded paint and leaded
paint-contaminated dust in housing; 3) continued reduction
of children’s exposure to lead in the environment; and 4)
establishment of nationwide surveillance for children with
elevated BLLs.
By the end of the 1990s, a new Healthy People 2010 target
had been established to eliminate BLLs >10 µg/dL among
children aged 1–5 years by 2010 (21). The baseline data used
to monitor progress toward this target are provided by
NHANES, which provides nationally representative and com-
parable estimates for monitoring trends but cannot determine
local variations in the risk for elevated BLLs (22,23). There-
fore, state and local data are necessary to develop effective
prevention measures and monitor their progress toward elimi-
nation of elevated BLLs.
Prevention Programs Established
CDC funds state and local programs to develop childhood
lead poisoning prevention programs and surveillance activi-
ties. The objectives of these childhood lead poisoning preven-
tion programs (CLPPPs) are to 1) screen infants and children
for elevated BLLs; 2) ensure that lead-poisoned infants and
children are referred for medical and environmental interven-
tion; 3) educate the public and health-care providers regard-
ing childhood lead poisoning; and 4) implement prevention
measures to reduce children’s exposure to lead.
Before child lead screening programs, neurologic findings
associated with acute encephalopathy were often the first signs
of lead poisoning, and children with these symptoms required
immediate hospitalization and treatment (24). Because symp-
toms are rare at BLLs <70 µg/dL, blood lead screening is nec-
essary to identify asymptomatic children with elevated BLLs.
Therefore, in 1991, CDC recommended universal screening
of children aged 12–72 months. However, a 1994 national
survey reported that only one fourth of young children had
been screened, including fewer than one third of those at
increased risk (e.g., because of poverty or residence in older
housing) (25). In addition, certain populations of children
were determined to be heavily exposed, whereas others were
only minimally exposed (26), depending on risk factors such
as poverty level and housing. Consequently, in 1997, CDC
recommended that states use data to develop plans to increase
screening and follow-up care for children who most need these
services. In the absence of a statewide plan or other formal
guidance from health officials, universal screening for all young
children was still recommended (27).
* 16 CFR § 1303.
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This report describes national trends in children’s BLLs >10
µg/dL obtained by using data from NHANES surveys (i.e.,
1976–1980, 1988–1991, 1991–1994 and 1999–2000) and
state data collected by the state Child Blood Lead Surveil-
lance (CBLS) system during 1997–2001. Also described is




Since the 1970s, the extent of human lead exposure has
been assessed in the United States by using NHANES, a
series of cross-sectional, nationally representative examination
surveys conducted by CDC’s National Center for Health Sta-
tistics. NHANES data indicate distribution of BLLs among
the national population, not at state or local levels. Each sur-
vey is a stratified, multistage, cluster sample of households
with a target population of civilian, noninstitutionalized resi-
dents of the United States (28). The surveys include a house-
hold interview and a standardized physical examination
conducted in a mobile examination center. This report
includes results from the first two years (1999–2000) of the
current NHANES, as well as previous results from NHANES
II (1976–1980), NHANES III, Phase 1 (1988–1991) and
NHANES III, Phase 2 (1991–1994).
As part of the NHANES physical examination, a 1 mL
sample of ethylenediaminetetraacetic acid-anticoagulated
whole blood was obtained by venipuncture from children aged
1–5 years. Blood specimens were frozen and shipped for analy-
sis from the survey sites to the NHANES Laboratory, Divi-
sion of Environmental Health Laboratory Sciences, National
Center for Environmental Health, CDC, Alanta, Georgia. All
analyses of BLLs were performed at CDC’s NHANES Labo-
ratory. The laboratory methods, including quality control and
assurance procedures, have been described previously (29,30).
Comparability has also been established for the method used
in NHANES II (i.e., modified Delves cup) and that used in
NHANES III and the current NHANES (i.e., graphite fur-
nace atomic absorption spectrophotometry). In all surveys,
blood lead measurements were calibrated by using standards
obtained from the National Institute of Standards and Tech-
nology, Gaithersburg, Maryland.
State and Local Surveillance
State and local childhood blood lead surveillance systems
are based on the results of blood lead tests of children aged
<72 months reported to state health departments by private
and state and local government laboratories. Reporting crite-
ria, such as the level that should be reported and who should
report, are set by each state and vary across jurisdictions. In
addition to funding multiple state programs, CDC also funds
certain city and county programs that forward surveillance
data to state health departments. Test results, which are com-
piled and analyzed by state health departments and submit-
ted annually to CDC, comprise the CBLS database.
In conjunction with staff from participating states, CDC
staff developed core data variables to be collected for every
child tested. These variables include identification and demo-
graphic information (e.g., date of birth, race, or ethnicity),
laboratory information (e.g., venous or capillary blood speci-
men), date of specimen collection, and test result. Individual
identifiers are stripped from the records, but each child is
assigned a unique identifier that is sent to CDC along with
the data. To assist CLPPPs with tracking the care of children
with elevated BLLs, CDC developed a computer software pro-
gram, Systematic Tracking of Elevated Lead Levels and
Remediation (STELLAR). Certain states use STELLAR; oth-
ers have developed their own programs.
CDC checks each state-submitted record for correct for-
matting and coding and inconsistent values. Records not meet-
ing CDC criteria are summarized in error reports that are sent
to states for correction. Certain errors, if not corrected, pre-
vent the record from being entered in CDC’s CBLS database.
A common error is an illogical sequence of dates on a labora-
tory record (i.e., date of test analysis is earlier than date blood
was drawn).
Analysis
In this report, state surveillance data are presented for chil-
dren aged <72 months who were tested for lead at least once
during 1997–2001. The following surveillance definitions are
used for all states:
Test: Any BLL sample (i.e., capillary, venous, or unknown
type) that produces a quantifiable result and is analyzed by a
Clinical Laboratory Improvement Amendments (CLIA)-
certified facility or an approved portable device. Blood for a
lead test can be collected for screening, confirmation, or fol-
low-up.
Screening test: A blood lead test for a child aged <72 months
who has not had a previously confirmed elevated BLL. A child
screened in multiple years or even multiple times within a
given year is counted only once for each year.
Confirmed elevated BLL: A child with one venous blood
specimen >10 µg/dL or two capillary blood specimens >10
µg/dL drawn within 12 weeks of each other (31,32).
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CLPPPs check for duplicate laboratory reports for children
and assign a unique identifier for each child before sending
the data to CDC. Children with confirmed elevated BLLs
who subsequently have another elevated test result, regardless
of test type, are included in the tables only once for each year
they had an elevated BLL test result. In subsequent years, chil-
dren with previously confirmed elevated BLLs but no follow-
up tests, or only follow-up tests with BLLs <10 µg/dL, are not
counted for those subsequent years.
We assign children with confirmed elevated BLLs into six
BLL groups with program relevance (i.e., >10 µg/dL to <15,
>15 to <20, >20 to <25, >25 to <45, >45 to <70, and >70).
The majority of states initiate follow-up testing at BLLs >10
µg/dL and environmental investigations at either >20 µg/dL
or persistent BLLs 15–19 µg/dL; chelation is recommended
for children with BLLs >45 µg/dL; and BLLs >70 µg/dL rep-
resent a medical emergency. These analyses are also catego-
rized by state, race or ethnicity, sex, and age group.
To assess the extent of testing among children using Medic-
aid services, a low-income group at high risk for elevated BLLs
(33), state and local health departments collaborate with their
Medicaid agencies to link blood lead surveillance data with
Medicaid data. This report presents data regarding which state
and local CLPPPs link surveillance and Medicaid data.
Population data in this report were obtained from the U.S.
Bureau of the Census. For each year, population data are only
included for states with reported surveillance data. Popula-
tion data used include intercensal population estimates for
1997–1999, the 2000 census, and postcensal estimates for
2001.
Statistical analyses for NHANES were performed with SAS
software (34) and SUDAAN® (35), a software package that
incorporates sample weights and adjusts analyses for the com-
plex sample design of the survey. Survey sample weights were
used in all analyses to produce estimates representative of the
noninstitutionalized, civilian U.S. population. Analyses of the
state surveillance data used SAS.
Results
National Surveys
The prevalence of BLLs >10 µg/dL in children aged 1–5
years living in the United States has continued to decline from
an estimated 88.2% during the 1976–1980 NHANES II sur-
vey (Figure 1). In 1999–2000, the prevalence estimate was
2.2% (95% confidence interval [CI] = 1.0%–4.3%) (Table 1).
By applying that prevalence to the U.S. population of chil-
dren in this age group, we estimated that 434,000 (95% CI =
189,000–846,000) children aged 1–5 years had elevated BLLs.
However, because of low prevalence of elevated BLLs and a
limited sample size, the NHANES 1999–2000 estimates are
highly variable.
State and Local Surveillance
By 2001, 44 states, the District of Columbia (DC), and
New York City (NYC) were submitting child blood lead sur-
veillance data to CDC. These sites represent 95% of the U.S.
population of children aged <72 months and 97% of pre-
1950 housing. By the end of 2001, all states with CDC-
associated CLPPPs were requiring laboratories to report results
of blood lead tests; however, states varied regarding the BLL
level at which results had to be reported (Table 2). In 2001,
29 (64.4%) of the participating jurisdictions required all BLLs
to be reported; 12 (26.7%) required reporting only for BLLs
>10 µg/dL; one (2.2%) required reporting only for BLLs >15
µg/dL; one (2.2%) required reporting only for BLLs >20 µg/
dL; and two (4.4%) required reporting only for BLLs >25
µg/dL.
Children Tested
The number of BLL-tested children reported to CDC
increased from 1,703,356 in 1997 (37 states, DC, and NYC)
to 2,422,298 in 2001 (44 states, DC, and NYC). For all years,
the largest group of children tested were aged 12–23 months,
followed by those aged 24–35 months (Table 3). Race or
ethnicity information was not collected (i.e., was unknown)
for approximately half of the children tested. For all years,
among the tested children for whom race or ethnicity was
reported (range: 57% in 1997 to 40.2% in 2001), approxi-
mately 43% were non-Hispanic whites, 35% were non-
Hispanic blacks, 15% were Hispanic, and 7% were of other
races or ethnicities (Table 4). For all years, slightly more boys
than girls were tested (Table 5). More than half of all tests
were conducted by six states and NYC (NYC 11.3%, Massa-
chusetts 10.1%, Illinois 7.7%, Texas 7.1%, New York 6.6%,
New Jersey 6%, and North Carolina 5%) (Table 6).
During 1997–2001, 28 states reported matching surveil-
lance and Medicaid data to assess the percentage of children
eligible for or receiving Medicaid services who had received a
blood lead test (Figure 2). However, these states used differ-
ent methods to assess lead testing among Medicaid-eligible or
Medicaid-enrolled children, making findings difficult to com-
pare. For example, certain states that link surveillance and
Medicaid data might also link these with birth records. Also,
states used different definitions for Medicaid-eligible and Med-
icaid-enrolled and different age cutoffs for analysis. Eight states
that matched Medicaid data with surveillance data reported
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that 17.2%–52.9% of Medicaid enrollees aged <72 months
had been tested for lead.
Confirmed Elevated BLLs
The number of children reported with confirmed elevated
BLLs steadily decreased from 130,512 in 1997 to 74,887 in
2001. Among children with elevated BLLs and known race or
ethnicity (range: 74.3% in 1997 to 63.6% in 2001), approxi-
mately 17% were non-Hispanic whites, 60% were non-
Hispanic blacks, 16% were Hispanic, and 7% were of other
races or ethnicities (Table 4). In each racial or ethnic group,
the number of children with elevated BLLs declined steadily
from 1997 to 2001. Each year, more boys than girls had
elevated BLLs (Table 5). Five states and NYC reported 54%
of the confirmed elevated BLLs in 2001 (Illinois, 20.5%; Ohio,
8.7%; Michigan, 6.8%; NYC, 6.6%; New York, 6.4%; and
Pennsylvania, 5.7%) (Table 6).
In 2001, 59.7% of children with elevated BLLs had levels
of 10–14 µg/dL; 21.3% had levels of 15–19 µg/dL; 9.2% had
levels of 20–24 µg/dL; 8.6% had levels of 25–44 µg/dL; 1%
had levels of 45–69 µg/dL; and 0.2% had levels >70 µg/dL
(Figure 3). In 2000, a total of 8,723 children (0.4% of those
tested) were reported with BLLs >25 µg/dL, the target for
elimination by 2000. In 2001, the number of children
reported with BLLs >25 µg/dL decreased to 7,342 (0.3% of
those tested). Among those with confirmed elevated BLLs and
reported race or ethnicity, the majority were non-Hispanic
blacks (Figure 4). Also, the largest numbers of children with
confirmed elevated BLLs were located in northeastern and
Midwestern states (Figure 5).
Pre-1950 Housing
The number of existing U.S. housing units built before 1950,
when paint had high lead content, decreased from 27.5 mil-
lion in 1990 to 25.8 million in 2000; however, pre-1950 hous-
ing units are located in all states (range: 12,472 in Alaska to
3,309,770 in New York). In 2000, approximately 80% of the
25.8 million pre-1950 housing units in the United States were
located in 21 states, and approximately 50% were located in
seven states (California, Illinois, Massachusetts, Michigan,
New York, Ohio, and Pennsylvania) (Figure 6).
Discussion
National surveys and state and local surveillance data both
indicate children’s BLLs continue to decline throughout the
United States. This decline reflects changes in national poli-
cies and laws implemented since the 1970s that have limited
the use of lead, including removal of lead from 1) gasoline,
2) food and soft-drink cans, 3) paint for residential use, and
4) solder in household plumbing (36). The greatest reduction
in children’s BLLs was observed between NHANES II (1976–
1980) and NHANES III, Phase I (1988–1991), suggesting
that past policies to reduce children’s exposure to lead have
succeeded. However, the Healthy People 2000 national goal to
eliminate BLLs >25 µg/dL among young children by 2000
was not achieved, and tens of thousands of children remain
exposed to lead.
 State and local surveillance data and previous NHANES
analyses indicate children who are non-Hispanic blacks or
Hispanic are more likely to have elevated BLLs than those
who are non-Hispanic whites (37). Although race or ethnicity
classification is missing for approximately half of those chil-
dren with elevated BLLs identified and reported in the state
and local surveillance data, these data suggest the number of
children with elevated BLLs has steadily declined in each of
these groups, which represent the three largest racial or ethnic
populations.
Another group previously determined to be at risk for
elevated BLLs is children from low-income families (4,38). In
a previous finding, Medicaid-eligible children represented 60%
of children with BLLs >10 µg/dL and 83% of those with BLLs
>20 µg/dL (39). However, despite their high risk for elevated
BLLs, only 19% of Medicaid-eligible children aged 1–5 years
had been tested for lead (40). CDC recommends that health-
care providers and health plans provide blood lead screening
and diagnostic and treatment services for children enrolled in
Medicaid (40), which routinely reimburses for such services.
State and local surveillance systems do not routinely include
Medicaid information because health-care providers rarely note
Medicaid status on test records. To better determine how many
Medicaid-eligible or Medicaid-enrolled children have been
tested for lead, states need to link their laboratory surveillance
data with Medicaid data. The majority of CLPPPs have
already made this link; however, different methodologies limit
comparisons among states. CDC will work with these pro-
grams to standardize linking and analysis and improve com-
parability among states.
Limitations
Findings from NHANES and state surveillance systems
should be viewed as complementary but not directly compa-
rable; substantial differences in methodology exist. Because
NHANES is based on a nationally representative sample,
estimates are only generalizable to the U.S. population. The
sample is not designed to provide estimates for smaller geo-
graphic areas or specific populations where the risk of elevated
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BLLs is high. Conversely, the CLPPPs provide data at state
and local levels that can be used to target screening and other
interventions to children at highest risk. However, not all chil-
dren at risk are tested. NHANES and CLPPPs also differ in
methods used to collect blood samples. For NHANES, all
blood lead tests are collected by venous sampling, a more
accurate method. In contrast, certain blood lead tests reported
to state health departments are collected by capillary sampling,
which can be contaminated if correct blood collection proce-
dures are not followed. Because of the risk for contamination
(41), elevated capillary tests should be confirmed by a venous
test or a second capillary test within 12 weeks. However,
because confirmatory testing does not always occur within 12
weeks, state data might underestimate children with elevated
BLLs, especially at levels of 10–14 µg/dL, among states that
do not recommend confirmatory testing at that BLL (42).
Also, for NHANES surveys, all samples are analyzed by the
CDC laboratory, which reports all test results. In contrast,
multiple laboratories analyze and report blood lead test
results to CLPPPs.
State-to-state comparisons of the numbers of children tested
and confirmed with elevated BLLs should be made cautiously,
with special attention given to varying state practices
(Table 2). State practices and policies that can affect assess-
ment of the lead problem include BLLs reported and the time
recommended for follow-up testing to confirm elevated BLLs.
Certain states are changing policies to improve their ability to
develop and assess prevention strategies; since 2001, two more
states have made all BLLs reportable for children. Because the
majority of children with elevated BLLs are asymptomatic, all
children at high risk should be tested; however, state testing
practices vary. Children in certain racial or ethnic groups (i.e.,
non-Hispanic blacks and Hispanics) are at increased risk for
elevated BLLs (18,33,37). CDC encourages collecting racial
and ethnic data; however, a high proportion of missing racial
data precludes the majority of states from knowing whether
they are adequately testing children at increased risk.
Conclusion
Successful surveillance requires states to track the test
results of substantial numbers of children. This has strained
old computer systems and created barriers to successful sub-
mission of complete data to CDC. Also, BLL tracking sys-
tems need to integrate data across programs. To improve
integration of data, increase states’ abilities to submit com-
plete data, and facilitate exchange of information for case
management (e.g., environmental inspection), CDC is devel-
oping a tracking module that will become part of CDC’s
Internet-based tracking and reporting system, the National
Electronic Disease Surveillance System (NEDSS) (43).
Reports published by states can differ from this report in
the numbers of children tested and identified with elevated
BLLs. CDC’s criteria for consistent dates and other data can
preclude certain records from being entered into the CDC
database. Also, certain states might publish data for older chil-
dren (i.e., aged >72 months) or use different definitions in
their analyses. Better comparability among states requires
increased use of a uniform national surveillance case defini-
tion (44) by public health officials and researchers. Compara-
bility is critical to accurately assess the number of children
with elevated BLLs and to monitor trends, including progress
toward the Healthy People 2010 goal of eliminating BLLs >10
µg/dL among young children.
Reducing BLLs can be a difficult and protracted process for
children with long-term exposure because lead accumulates
in bones and is released slowly over time. Chelation, the only
available medical therapy, has side effects and risks, might not
reverse harmful effects, and does not effectively reduce BLLs
in children with moderate exposure (45). CDC and others
recommend screening the environment for lead to prevent
exposure to children (46–50). Identifying sources of lead
exposure can be challenging, especially for children who move
or spend time in multiple locations. Effective identification
of pre-1950 housing where young children live or are likely to
live requires assessment of data from multiple sources (e.g.,
tax assessor, census, Medicaid, and child blood lead surveil-
lance) and improved partnerships with other programs (e.g.,
prenatal care; home visits for newborns; the Women, Infants,
and Children nutritional program; immunizations; and hous-
ing subsidies).
Elevated BLLs among young children can be eliminated by
state and local prevention activities. Beginning in 2003, state
and local health departments funded by CDC for childhood
lead poisoning prevention programs are required to develop
formal elimination plans. Certain jurisdictions (i.e., Minne-
sota, Boston, Chicago, and Cleveland) already have convened
lead elimination workgroups involving key representatives
from health, housing, banking, and other areas involved in
children’s health and welfare. A critical factor in any elimina-
tion plan is use of local data to define and address local prob-
lems. Key elements for effective targeting strategies include
1) enacting state laws requiring reporting of all BLLs, 2) link-
ing state-level environmental and Medicaid enrollment data,
3) improving overall data quality, and 4) streamlining report-
ing through NEDSS.
CDC will continue to urge CLPPPs to direct interventions
at areas with the greatest demonstrated problems, and at popu-
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lations with the highest risks. State and local data, in combi-
nation with NHANES, will enable us to continue monitor-
ing progress toward elimination of elevated BLLs among all
young children.
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FIGURE 1. Blood lead levels >10 µg/dL among children aged
1–5 years — United States, 1976–1980, 1988–1991, 1991–1994,
and 1999–2000*
Source: National Health and Nutrition Examination Surveys (NHANES).
Note: In 1991, NHANES III Phase 1 was completed and Phase 2 was begun.

















FIGURE 2. State programs linking childhood blood lead and






FIGURE 3. Number of children with confirmed blood lead levels
(BLLs) >10 µg/dL by program-relevant age group and BLL
group — selected U.S. states, 2001

























FIGURE 4. Number of children with confirmed blood lead levels
(BLLs) >10 µg/dL by racial or ethnic group and program-
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FIGURE 5. Number of children with confirmed
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FIGURE 6. Number of pre-1950 housing units and children with
confirmed elevated blood lead levels (EBLLs) >10 µg/dL — selected
U.S. sites, 2001




































States with <150,000 units*
Pre-1950 housing units
2001 confirmed EBLLs
Pre-1950 housing units (thousands)
Number of confirmed EBLLS, 2001
0 4,000 8,000 12,000 16,000
* Arkansas, Arizona, Delaware, District of Columbia, Hawaii, Montana, New Mexico,
New York City, Utah, Vermont, and Wyoming.
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TABLE 1. Estimated prevalence* of children aged 1–5 years with blood
lead levels (BLLs) >10 µg/dL† — United States, 1976–1980, 1988–1991,
1991–1994, and 1999–2000
Prevalence of
BLLs >10 µg/dL  Children with BLLs >10 µg/dL
Survey (%) (95% CI§) No.   (95% CI)
1976–1980 88.2 (83.8–92.6) 13,500,000 (12,800,000–14,100,000)
1988–1991 8.6¶ (4.8–12.4) 1,700,000 (960,000–2,477,000)
1991–1994 4.4 (2.9–6.6 ) 890,000 (590,000–1,330,000)
1999–2000 2.2** (1.0–4.3) 434,000** (189,000–846,000)
Source: National Health and Nutrition Examination Surveys (NHANES).
Note: In 1991, NHANES III Phase 1 was completed and Phase 2 was begun.
* Estimated number of children aged 1–5 years with BLLs >10 µg/dL divided by esti-
mated population of children aged 1–5 years.
† CDC has determined BLL >10 µg/dL is a level of concern.
§ Confidence interval.
¶ Estimate differs slightly from that published previously because of updates in coding
and weighting of survey data.
** Data for 1999–2000 are highly variable (relative standard error >30%).
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TABLE 2. Selected state policies that affect interpretation of blood lead level (BLL) data collected and reported by childhood lead
poisoning prevention programs — United States sites, 1997–2001
Confirmatory testing
When screening Minimum BLL that should Time recommended Surveillance
is required or have follow-up for to obtain Reportable
State recommended confirmation (µg/dL) confirmatory test BLL (µg/dL) Who reports
Alabama r, hr, u, E* 10 3 mos >10 p, l†
Alaska r, hr 10 3 mos >10 p, l
Arizona p, u, E 10 30 days all p, l
California p, hrp, E 10 3 mos >25 p, l
Colorado r, hr, E 10 1–3 mos >10 p, l
Connecticut r, hr, E 10 3 mos all§ p, l
District of Columbia r, dc, u, s, hr 15 1 wk >10 p, l
Delaware r, dc, s, hr, p, u 10 3 mos all l
Florida E, hr, p, r 10 3 mos >10 p, l
Georgia r, p, E 10 3 mos >10 p, l, o2,3
Hawaii p, E 10 3 mos all p, l
Illinois dc, hr, s, E, M 10 3 mos all p, l
Indiana E 10 3–4 mos all l
Iowa E 10 3–4 mos all p, l
Kansas r, hr, p, u, E 10 3 mos >10 p, l, o2,3
Kentucky u, E 20 1–4 wks >25 p, l, o2
Louisiana r, p, u, E 10 3 mos all p, l, o2,3
Maine r, hr, E, M 10¶ 1 month >20 l
Maryland r, p, dc, hr, E 10 3 mos all l
Massachusetts hr, dc, s, p, u, E 10 90 days >15 l
Michigan r, hr, E 10 3–4 mos all l
Minnesota r, hr, E 10 3 mos all l
Missouri p, u, r, hr, dc, E 10 2–3 mos all p, l, o3
Montana r, hr 10 1 mos >10 p, l
Nebraska r, p, hr, E 10 3–4 mos all p, l
New Hampshire r, hr, E 10 6 mos all p, l
New Jersey p, u, E 10 3 mos all l
New Mexico r, p, hr, E 10 3 mos all p, l, o1
New York u 10 3–4 mos all p, l, o2,3
North Carolina hr, E 10 6 mos all l
Ohio r, hr, E 10 3 mos all l
Oklahoma hr, p, E 10 3 mos >10 p, l
Oregon r, hr, E 10 3 mos all p, l
Pennsylvania p, hr, u, E 10 3 mos all l
Rhode Island u 10 3 mos all p, l
South Carolina u 10 3 mos all p, l, o3
Tennessee r, hr, E 10 3 mos all p, l
Texas p, E 10 3–4 mos >10 p, l
Utah r, hr, p, E 10 3 mos >10 p, l, o2,3
Vermont u 15** 3 mos all p, l
Virginia hr, E 10 3 mos >10 p, l
Washington r 10 6 mos all l
West Virginia u, E 10 3 mos all p, l
Wisconsin E, p, r, hr 10 3 mos all p, l
Wyoming r, hr, p, u, E 10 3–4 mos all l
Source: Adapted from National Conference of State Legislatures. State activities in lead poisoning prevention, 2002.
* dc before entering day care
E Early and Periodic Screening, Diagnosis, and Treatment program regulations (requires blood lead test of all Medicaid eligible children)
hr lives in high-risk area
hrp high-risk population
M targeted screen of Medicaid children
p pediatricians screen
r upon request
s before entering school





3 local health agencies and industries
4 all children <6 years old have blood lead samples analyzed only at state public health lab
p pediatricians or other physicians
§ Before October 1998 only BLLs >10 µg/dL were reportable.
¶ Confirmatory testing only for BLLs >15 µg/dL during January 1997–June 1998.
** Medicaid confirms tests at BLLs >10 µg/dL.
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TABLE 3. Children aged <72 months for whom blood lead surveillance data were reported to CDC and number of children
confirmed to have blood lead levels (BLLs) >10 µg/dL by year, age group, and BLL group — selected U.S. sites, 1997–2001
No. aged Total Confirmed
<72 mos no. with BLLs
for states confirmed* >10 µg/dL No. with confirmed BLLs >10 µg/dL by their
Age submitting BLLs among highest BLL (µg/dL) at or after confirmation
Year group (mos) data No. tested >10 µg/dL tested (%) 10–14† 15–19†  20–24† 25–44 45–69 >70
1997 0–11 3,234,558 210,953 4,534 2.15 2,789 922 427 361 30 5
12–23 3,208,065 426,891 26,801 6.28 14,124 6,002 3,197 3,057 375 46
24–35 3,257,559 307,957 29,483 9.57 15,765 6,667 3,369 3,214 386 82
36–47 3,301,714 279,412 27,707 9.92 15,363 6,506 3,028 2,557 213 40
48–59 3,401,339 288,863 25,303 8.76 14,820 5,757 2,535 2,014 157 20
60–71 3,469,679 189,280 16,684 8.81 9,955 3,830 1,649 1,148 86 16
Total 19,872,914 1,703,356 130,512 7.66 72,816 29,684 14,205 12,351 1,247 209
1998 0–11 3,446,646 220,652 4,151 1.88 2,625 852 341 314 17 2
12–23 3,410,464 462,849 25,685 5.55 14,087 5,779 2,834 2,614 316 55
24–35 3,415,630 310,760 26,280 8.46 14,365 5,973 2,823 2,743 319 57
36–47 3,461,075 278,701 24,031 8.62 13,930 5,422 2,426 2,008 218 27
48–59 3,554,842 283,857 21,863 7.70 13,473 4,765 1,985 1,501 129 10
60–71 3,604,969 180,089 14,522 8.06 8,966 3,236 1,302 927 85 6
Total 20,893,626 1,736,908 116,532 6.71 67,446 26,027 11,711 10,107 1,084 157
1999 0–11 3,549,859 231,121 3,274 1.42 1,980 674 273 308 33 6
12–23 3,490,917 519,475 21,374 4.11 12,001 4,719 2,263 2,122 241 28
24–35 3,493,098 331,060 21,626 6.53 12,007 4,914 2,304 2,102 267 32
36–47 3,492,478 274,480 18,928 6.90 11,322 4,113 1,832 1,501 137 23
48–59 3,584,866 277,676 16,677 6.01 10,328 3,612 1,441 1,190 99 7
60–71 3,626,499 175,729 11,356 6.46 7,101 2,514 989 691 49 12
Total 21,237,717 1,809,541 93,235 5.15 54,739 20,546 9,102 7,914 826 108
2000 0–11 3,586,594 270,824 3,252 1.20 2,014 643 269 291 32 3
12–23 3,600,669 645,586 20,825 3.23 11,827 4,454 2,215 2,063 224 42
24–35 3,573,765 412,905 21,576 5.23 12,198 4,641 2,223 2,212 247 55
36–47 3,615,334 314,052 17,523 5.58 10,528 3,753 1,616 1,438 163 25
48–59 3,704,678 302,453 14,575 4.82 9,040 3,094 1,253 1,067 107 14
60–71 3,743,359 190,112 9,806 5.16 6,115 2,108 843 678 52 10
Total 21,824,399 2,135,932 87,557 4.10 51,722 18,693 8,419 7,749 825 149
2001 0–11 3,674,701 321,267 2,774 0.86 1,697 558 232 262 22 3
12–23 3,689,097 738,122 18,681 2.53 10,700 4,124 1,843 1,784 196 34
24–35 3,660,883 476,408 18,905 3.97 10,934 3,978 1,875 1,814 260 44
36–47 3,702,419 355,764 14,998 4.22 9,043 3,201 1,385 1,208 135 26
48–59 3,793,982 329,250 11,853 3.60 7,440 2,481 954 872 100 6
60–71 3,833,419 201,487 7,676 3.81 4,916 1,601 583 524 47 5
Total 22,354,501§ 2,422,298 74,887 3.09 44,730 15,943 6,872 6,464 760 118
* Confirmed by either one elevated venous test or two elevated capillary tests <12 weeks apart.
†
BLL group may be underreported. Certain states do not report BLLs 10–24 µg/dL (see Table 2).
§
Detailed census data were not available. Differences in 2001 total population estimates are due to rounding.
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TABLE 4. Children aged <72 months for whom blood lead surveillance data were reported to CDC and number of children confirmed
to have blood lead levels (BLLs) >10 µg/dL by year, racial or ethnic group, and BLL group — selected U.S. sites, 1997–2001
No. aged Total Confirmed
<72 mos no. with BLLs
for states confirmed* >10 µg/dL No. with confirmed BLLs >10 µg/dL by their
Racial or submitting No. BLLs among highest BLL (µg/dL) at or after confirmation
Year ethnic group data tested >10 µg/dL tested (%) 10–14† 15–19†  20–24† 25–44 45–69 >70
1997 White, non-Hispanic 12,564,418 419,428 15,713 3.75 9,124 3,516 1,561 1,365 126 21
Black, non-Hispanic 2,603,363 359,505 63,458 17.65 32,969 15,296 7,785 6,650 642 116
Native American/
Alaska Native 148,765 5,951 327 5.49 177 70 33 42 4 1
Asian/Pacific Islander 847,029 19,697 1,562 7.93 832 272 208 202 39 9
Hispanic 3,709,339 151,833 14,383 9.47 7,748 3,105 1,685 1,624 190 31
Other/Multiracial 17,861 1,571 8.80 819 383 168 175 24 2
Unknown 729,081 33,498 4.59 21,147 7,042 2,765 2,293 222 29
Total 19,872,914 1,703,356 130,512 7.66 72,816 29,684 14,205 12,351 1,247 209
1998 White, non-Hispanic 13,039,219 401,830 13,426 3.34 7,817 2,995 1,305 1,169 123 17
Black, non-Hispanic 2,930,480 358,241 54,177 15.12 29,358 12,854 6,121 5,238 541 65
Native American/
Alaska Native 150,921 6,330 286 4.52 152 70 30 29 4 1
Asian/Pacific Islander 950,638 20,984 1,432 6.82 738 292 185 182 28 7
Hispanic 3,822,368 135,728 12,132 8.94 6,692 2,481 1,418 1,340 168 33
Other/Multiracial 16,323 1,160 7.11 689 251 98 106 14 2
Unknown 797,472 33,919 4.25 22,000 7,084 2,554 2,043 206 32
Total 20,893,626 1,736,908 116,532 6.71 67,446 26,027 11,711 10,107 1,084 157
1999 White, non-Hispanic 13,138,722 408,672 11,391 2.79 6,546 2,634 1,074 1,041 81 15
Black, non-Hispanic 2,888,002 339,813 41,471 12.20 23,140 9,627 4,480 3,808 374 42
Native American/
Alaska Native 178,593 9,745 251 2.58 139 55 20 33 3 1
Asian/Pacific Islander 977,235 19,874 1,172 5.90 583 247 173 135 31 3
Hispanic 4,055,165 139,028 10,180 7.32 5,641 2,050 1,154 1,170 145 20
Other/Multiracial 18,323 1,002 5.47 584 230 84 88 10 6
Unknown 874,086 27,768 3.18 18,106 5,703 2,117 1,639 182 21
Total 21,237,717 1,809,541 93,235 5.15 54,739 20,546 9,102 7,914 826 108
2000 White, non-Hispanic 12,666,345 414,833 10,250 2.47 6,037 2,216 982 908 93 14
Black, non-Hispanic 3,043,966 325,086 34,483 10.61 19,569 7,926 3,562 3,066 303 57
Native American/
Alaska Native 185,763 13,717 234 1.71 135 58 17 19 4 1
Asian/Pacific Islander 806,149 21,886 1,084 4.95 562 214 132 152 19 5
Hispanic 4,339,913 154,962 9,685 6.25 5,275 2,056 1,097 1,107 127 23
Other/Multiracial 782,263 17,029 869 5.10 507 181 72 93 12 4
Unknown 1,188,419 30,952 2.60 19,637 6,042 2,557 2,404 267 45
Total 21,824,399 2,135,932 87,557 4.10 51,722 18,693 8,419 7,749 825 149
2001 White, non-Hispanic 13,030,940 433,317 8,738 2.02 5,134 1,948 849 707 83 17
Black, non-Hispanic 3,148,325 327,126 28,291 8.65 16,460 6,334 2,731 2,431 300 35
Native American/
Alaska Native 187,319 15,161 230 1.52 126 54 23 23 4 0
Asian/Pacific Islander 814,671 20,355 901 4.43 428 186 121 148 16 2
Hispanic 4,376,784 154,723 8,625 5.57 4,630 1,834 988 1,032 119 22
Other/Multiracial 796,461 22,073 872 3.95 503 177 88 90 12 2
Unknown 1,449,543 27,230 1.88 17,449 5,410 2,072 2,033 226 40
Total 22,354,500§ 2,422,298 74,887 3.09 44,730 15,943 6,872 6,464 760 118
* Confirmed by either one elevated venous test or two elevated capillary tests <12 weeks apart.
†
BLL group may be underreported. Certain states do not report BLLs 10–24 µg/dL (see Table 2).
§
Detailed census data were not available. Differences in 2001 total population estimates are due to rounding.
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TABLE 5. Children aged <72 months for whom blood lead surveillance data were reported to CDC and number of children
confirmed to have blood lead levels (BLLs) >10 µg/dL by year, sex, and BLL group — selected U.S. sites, 1997–2001
No. aged Total Confirmed
<72 mos no. with BLLs
for states confirmed* >10 µg/dL No. with confirmed BLLs >10 µg/dL by their
submitting BLLs among highest BLL (µg/dL) at or after confirmation
Year Sex data No. tested >10 µg/dL tested (%) 10–14† 15–19†  20–24† 25–44 45–69 >70
1997 Male 10,164,518 850,881 69,420 8.16 38,344 16,051 7,674 6,586 645 120
Female 9,708,396 798,763 58,955 7.38 33,096 13,195 6,349 5,637 590 88
Unknown 53,712 2,137 3.98 1,376 438 182 128 12 1
Total 19,872,914 1,703,356 130,512 7.66 72,816 29,684 14,205 12,351 1,247 209
1998 Male 10,686,510 879,369 62,466 7.10 35,967 14,059 6,362 5,455 547 76
Female 10,207,116 805,709 51,938 6.45 30,076 11,501 5,227 4,532 523 79
Unknown 51,830 2,128 4.11 1,403 467 122 120 14 2
Total 20,893,626 1,736,908 116,532 6.71 67,446 26,027 11,711 10,107 1,084 157
1999 Male 10,858,067 898,937 49,854 5.55 29,108 11,104 4,914 4,235 437 56
Female 10,379,650 848,600 41,430 4.88 24,447 8,994 4,036 3,527 378 48
Unknown 62,004 1,951 3.15 1,184 448 152 152 11 4
Total 21,237,717 1,809,541 93,235 5.15 54,739 20,546 9,102 7,914 826 108
2000 Male 11,167,766 1,078,922 46,613 4.32 27,412 9,977 4,554 4,147 453 70
Female 10,656,633 982,792 38,845 3.95 22,952 8,300 3,722 3,442 352 77
Unknown 74,218 2,099 2.83 1,358 416 143 160 20 2
Total 21,824,399 2,135,932 87,557 4.10 51,722 18,693 8,419 7,749 825 149
2001 Male 11,439,685 1,225,187 40,067 3.27 23,817 8,570 3,729 3,471 418 62
Female 10,914,827 1,106,532 33,051 2.99 19,754 7,023 3,026 2,859 335 54
Unknown 90,579 1,769 1.95 1,159 350 117 134 7 2
Total 22,354,512§ 2,422,298 74,887 3.09 44,730 15,943 6,872 6,464 760 118
* Confirmed by either one elevated venous test or two elevated capillary tests <12 weeks apart.
†
BLL group may be underreported. Certain states do not report BLLs 10–24 µg/dL (see Table 2).
§
Detailed census data were not available. Differences in 2001 total population estimates are due to rounding.
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TABLE 6. Children aged <72 months for whom blood lead surveillance data were reported to CDC and number of children
confirmed to have blood lead levels (BLLs) >10 µg/dL by state, year and BLL group — selected U.S. sites, 1997–2001
No. aged Total Confirmed
<72 mos no. with BLLs
for states confirmed* >10 µg/dL No. with confirmed BLLs >10 µg/dL by their
submitting BLLs among highest BLL (µg/dL) at or after confirmation
State Year data No. tested >10 µg/dL tested (%) 10–14† 15–19†  20–24† 25–44 45–69 >70
Alabama 1997 357,087 22,880 1,501 6.56 889 411 120 76 5 0
1998 352,409 17,844 992 5.56 586 253 86 61 6 0
1999 349,592 17,657 546 3.09 342 114 43 41 6 0
2000 356,676 13,702 316 2.31 204 64 20 21 7 0
2001 357,111 12,077 654 5.42 400 131 62 56 5 0
Alaska 1997 60,266 142 2 1.41 1 1 0 0 0 0
1998 60,271 242 2 0.83 2 0 0 0 0 0
1999 60,247 103 1 0.97 1 0 0 0 0 0
2000 57,620 73 1 1.37 0 1 0 0 0 0
2001 57,773 51 3 5.88 3 0 0 0 0 0
Arizona 1997 —§ — — — — — — — — —
1998 — — — — — — — — — —
1999 462,341 1,929 168 8.71 93 42 12 18 3 0
2000 459,141 7,247 181 2.50 105 35 19 20 2 0
2001 463,085 8,026 170 2.12 109 34 10 17 0 0
California 1997 3,204,502 12,403 2,281 18.39 566 679 544 433 52 7
1998 3,104,123 11,800 1,848 15.66 491 545 429 341 37 5
1999 3,029,049 10,070 1,565 15.54 372 474 356 319 37 7
2000 3,018,386 12,717 1,475 11.60 398 412 307 319 32 7
2001 3,034,623 15,040 1,402 9.32 325 443 281 321 27 5
Colorado 1997 331,728 5,077 180 3.55 108 36 16 17 2 1
1998 339,604 4,150 124 2.99 77 24 6 14 3 0
1999 345,246 3,815 102 2.67 64 20 10 7 1 0
2000 357,202 6,606 112 1.70 71 21 7 12 1 0
2001 359,896 8,983 112 1.25 62 20 18 12 0 0
Connecticut 1997 260,336 65,063 3,000 4.61 1,581 709 357 311 41 1
1998 261,163 52,942 2,384 4.50 1,266 538 291 258 28 3
1999 263,845 62,163 2,057 3.31 1,196 439 204 188 28 2
2000 270,187 64,017 2,362 3.69 1,342 521 255 216 26 2
2001 270,763 66,333 1,977 2.98 1,170 445 187 153 20 2
Delaware 1997 — — — — — — — — — —
1998 59,695 8,728 226 2.59 115 54 29 26 1 1
1999 60,211 10,354 210 2.03 108 48 26 26 2 0
2000 62,122 9,505 159 1.67 86 30 22 19 2 0
2001 62,380 14,329 150 1.05 82 41 11 15 1 0
District of 1997 39,660 192 153 79.69 9 33 55 50 6 0
Columbia 1998 35,348 8,914 453 5.08 235 105 54 49 9 1
1999 33,320 14,314 502 3.51 305 92 46 55 4 0
2000 39,326 15,138 404 2.67 250 85 35 29 4 1
2001 39,356 16,036 437 2.73 287 74 29 44 3 0
Florida 1997 1,152,887 38,801 2,347 6.05 1,592 486 142 109 13 5
1998 1,154,343 33,803 2,146 6.35 1,495 396 138 110 7 0
1999 1,149,495 34,389 1,509 4.39 967 347 108 75 10 2
2000 1,142,293 45,895 723 1.58 467 149 40 58 9 0
2001 1,149,277 61,788 633 1.02 391 134 56 49 3 0
Note: State data and analysis may vary from CDC data because of strict CDC guidelines and criteria.
* Confirmed by either one elevated venous test or two elevated capillary tests <12 weeks apart.
† BLL group may be underreported. Certain states do not report BLLs 10–24 µg/dL (see Table 2).
§ Data unavailable for analysis or state surveillance system not in place.
¶ Statewide surveillance start-up year.
** CDC does not have complete dataset.
†† Detailed census data were not available. Differences in 2001 total population estimates are due to rounding.
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TABLE 6. (Continued) Children aged <72 months for whom blood lead surveillance data were reported to CDC and number of
children confirmed to have blood lead levels (BLLs) >10 µg/dL by state, year and BLL group — selected U.S. sites, 1997–2001
No. aged Total Confirmed
<72 mos no. with BLLs
for states confirmed* >10 µg/dL No. with confirmed BLLs >10 µg/dL by their
submitting BLLs among highest BLL (µg/dL) at or after confirmation
State Year data No. tested >10 µg/dL tested (%) 10–14† 15–19†  20–24† 25–44 45–69 >70
Georgia 1997 — — — — — — — — — —
1998 685,213 22,492 445 1.98 247 121 41 36 0 0
1999 694,317 20,419 508 2.49 279 130 42 50 7 0
2000 714,090 27,392 466 1.70 275 107 37 43 3 1
2001 718,870 32,955 423 1.28 269 89 26 38 0 1
Hawaii 1997 — — — — — — — — — —
1998 101,124 3,724 99 2.66 58 28 11 2 0 0
1999 97,480 4,898 105 2.14 71 20 6 8 0 0
2000 94,446 7,349 84 1.14 47 20 7 6 4 0
2001 94,748 9,174 42 0.46 26 7 5 3 1 0
Illinois 1997 1,089,142 179,462 32,061 17.87 17,787 7,784 3,082 3,030 319 59
1998 1,071,765 174,112 25,721 14.77 15,471 5,429 2,368 2,154 250 49
1999 1,061,071 168,874 20,733 12.28 12,708 4,307 1,774 1,736 178 30
2000 1,059,514 176,712 18,189 10.29 11,102 3,745 1,668 1,473 162 39
2001 1,061,668 187,385 15,323 8.18 9,308 3,264 1,323 1,249 155 24
Indiana 1997 494,918 32,011 910 2.84 543 185 88 75 16 3
1998 495,192 28,603 727 2.54 385 180 84 69 9 0
1999 497,865 27,280 751 2.75 430 179 72 68 1 1
2000 508,845 28,143 624 2.22 375 131 66 45 6 1
2001 509,812 26,903 611 2.27 350 148 67 42 4 0
Iowa 1997 220,872 25,239 1,414 5.60 748 357 157 134 16 2
1998 220,543 26,174 1,291 4.93 691 288 128 163 16 5
1999 220,379 27,724 1,049 3.78 548 234 125 128 13 1
2000 227,062 29,793 1,040 3.49 549 247 121 103 18 2
2001 227,171 36,841 1,063 2.89 576 238 112 110 24 3
Kansas 1997¶ 217,762 36 3 8.33 1 0 0 2 0 0
1998 219,444 3,482 71 2.04 24 24 7 14 2 0
1999 220,941 4,009 224 5.59 108 61 26 27 2 0
2000 226,862 7,224 222 3.07 120 50 16 31 5 0
2001 227,151 10,706 320 2.99 189 61 33 32 4 1
Kentucky 1997 — — — — — — — — — —
1998 — — — — — — — — — —
1999 — — — — — — — — — —
2000¶ 320,380 15,844 142 0.90 65 29 20 25 3 0
2001 320,916 24,167 317 1.31 157 60 46 47 3 4
Louisiana 1997 — — — — — — — — — —
1998 379,751 23,168 551 2.38 227 152 82 81 6 3
1999 378,280 21,587 690 3.20 318 191 94 76 10 1
2000 381,826 30,804 1,023 3.32 484 270 137 122 8 2
2001 381,856 44,456 1,060 2.38 563 249 118 124 3 3
Maine 1997 84,280 12,222 514 4.21 330 103 41 34 4 2
1998 82,130 10,064 396 3.93 262 76 26 31 1 0
1999 81,394 9,692 340 3.51 194 86 30 28 2 0
2000 85,915 10,242 333 3.25 209 65 30 20 8 1
2001 86,075 11,361 332 2.92 209 63 32 24 2 2
Note: State data and analysis may vary from CDC data because of strict CDC guidelines and criteria.
* Confirmed by either one elevated venous test or two elevated capillary tests <12 weeks apart.
† BLL group may be underreported. Certain states do not report BLLs 10–24 µg/dL (see Table 2).
§ Data unavailable for analysis or state surveillance system not in place.
¶ Statewide surveillance start-up year.
** CDC does not have complete dataset.
†† Detailed census data were not available. Differences in 2001 total population estimates are due to rounding.
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TABLE 6. (Continued) Children aged <72 months for whom blood lead surveillance data were reported to CDC and number of
children confirmed to have blood lead levels (BLLs) >10 µg/dL by state, year and BLL group — selected U.S. sites, 1997–2001
No. aged Total Confirmed
 <72 mos no. with BLLs
for states confirmed* >10 µg/dL No. with confirmed BLLs >10 µg/dL by their
submitting BLLs among highest BLL (µg/dL) at or after confirmation
State Year data No. tested >10 µg/dL tested (%) 10–14† 15–19†  20–24† 25–44 45–69 >70
Maryland 1997** 422,725 2,049 1,806 88.14 345 455 568 408 25 5
1998** 418,567 2,186 1,912 87.47 362 762 470 286 28 4
1999** 418,912 2,021 1,425 70.51 345 523 327 209 18 3
2000 427,939 67,516 2,668 3.95 1,698 552 223 178 14 3
2001 429,749 74,925 2,114 2.82 1,392 427 136 144 12 3
Massachusetts 1997 480,892 241,872 7,810 3.23 5,197 1,531 629 423 27 3
1998 474,905 240,544 6,453 2.68 4,333 1,301 452 335 31 1
1999 473,447 254,858 5,458 2.14 3,743 1,007 399 279 28 2
2000 480,422 251,872 4,395 1.74 3,069 766 280 247 26 7
2001 481,406 244,173 3,620 1.48 2,498 651 249 205 12 5
Michigan 1997 804,560 23,648 4,028 17.03 2,050 906 546 484 39 3
1998 793,691 61,975 6,810 10.99 4,105 1,460 611 563 65 6
1999 792,123 75,648 6,038 7.98 3,566 1,324 613 484 46 5
2000 814,505 78,164 4,697 6.01 2,933 988 388 353 31 4
2001 815,894 83,867 5,109 6.09 3,248 1,033 422 348 49 9
Minnesota 1997 383,055 37,413 1,871 5.00 1,098 398 201 151 18 5
1998 384,854 35,653 1,552 4.35 918 340 138 134 16 6
1999 387,695 36,727 1,215 3.31 734 258 111 94 15 3
2000 397,581 41,185 1,019 2.47 584 218 96 106 12 3
2001 398,895 47,096 1,080 2.29 638 222 104 100 11 5
Missouri 1997 443,042 41,770 5,061 12.12 2,828 1,200 542 441 42 8
1998 438,960 44,465 5,046 11.35 2,934 1,168 448 434 56 6
1999 437,313 48,974 4,783 9.77 2,787 1,146 417 384 46 3
2000 445,566 56,888 4,935 8.67 2,895 1,149 389 458 41 3
2001 446,404 65,088 3,342 5.13 2,084 707 278 238 33 2
Montana 1997 65,423 858 41 4.78 29 7 4 0 1 0
1998 64,823 1,133 30 2.65 24 5 1 0 0 0
1999 64,143 3,402 19 0.56 16 2 0 1 0 0
2000 66,452 2,394 18 0.75 13 4 1 0 0 0
2001 66,511 2,208 6 0.27 4 1 1 0 0 0
Nebraska 1997 137,189 5,167 312 6.04 164 61 32 48 6 1
1998 137,375 8,496 355 4.18 188 78 37 40 10 2
1999 138,005 11,114 395 3.55 207 84 51 46 6 1
2000 141,081 13,867 311 2.24 159 61 40 41 6 4
2001 141,261 14,514 295 2.03 163 65 30 33 4 0
New Hampshire 1997 89,518 15,775 502 3.18 269 118 54 57 4 0
1998 89,254 15,237 534 3.50 301 123 64 42 4 0
1999 89,711 14,346 553 3.85 319 137 52 39 4 2
2000 92,378 13,973 501 3.59 317 117 38 27 1 1
2001 92,820 13,508 391 2.89 247 84 24 34 2 0
New Jersey 1997** 677,474 12,541 2,938 23.43 851 515 775 705 78 14
1998** 665,655 11,183 2,350 21.01 685 390 617 585 67 6
1999** 657,145 8,230 1,712 20.80 494 302 466 385 60 5
2000 681,609 135,262 3,820 2.82 1,438 667 788 800 105 22
2001 683,569 146,428 2,998 2.05 1,198 589 525 580 98 8
Note: State data and analysis may vary from CDC data because of strict CDC guidelines and criteria.
* Confirmed by either one elevated venous test or two elevated capillary tests <12 weeks apart.
† BLL group may be underreported. Certain states do not report BLLs 10–24 µg/dL (see Table 2).
§ Data unavailable for analysis or state surveillance system not in place.
¶ Statewide surveillance start-up year.
** CDC does not have complete dataset.
†† Detailed census data were not available. Differences in 2001 total population estimates are due to rounding.
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TABLE 6. (Continued) Children aged <72 months for whom blood lead surveillance data were reported to CDC and number of
children confirmed to have blood lead levels (BLLs) >10 µg/dL by state, year and BLL group — selected U.S. sites, 1997–2001
No. aged Total Confirmed
<72 mos no. with BLLs
for states confirmed* >10 µg/dL No. with confirmed BLLs >10 µg/dL by their
submitting BLLs among highest BLL (µg/dL) at or after confirmation
State Year data No. tested >10 µg/dL tested (%) 10–14† 15–19†  20–24† 25–44 45–69 >70
New Mexico 1997 162,814 5,833 71 1.22 43 12 4 10 1 1
1998 160,514 4,500 24 0.53 9 9 5 1 0 0
1999 158,269 4,488 29 0.65 17 7 5 0 0 0
2000 157,439 3,251 23 0.71 18 3 1 1 0 0
2001 157,696 2,695 39 1.45 24 9 2 4 0 0
New York 1997 884,716 212,860 13,120 6.16 7,910 2,963 1,172 1,002 65 8
(excluding 1998 846,487 198,030 10,610 5.36 6,463 2,495 891 686 68 7
New York City) 1999 821,562 187,282 6,777 3.62 4,233 1,459 554 486 38 7
2000 861,874 185,016 6,391 3.45 3,976 1,357 546 447 56 9
2001 863,100 159,997 4,814 3.01 2,973 1,074 381 344 36 6
New York City 1997 670,352 333,488 12,507 3.75 9,246 1,708 773 681 81 18
1998 658,254 292,282 10,493 3.59 7,266 1,864 662 623 66 12
1999 648,360 259,865 7,927 3.05 5,575 1,337 502 451 53 9
2000 639,087 285,343 6,826 2.39 4,826 1,236 364 350 45 5
2001 639,380 272,947 4,957 1.82 3,369 941 303 303 36 5
North Carolina 1997 629,399 97,167 1,259 1.30 718 313 120 95 11 2
1998 636,257 96,728 1,067 1.10 641 257 78 83 8 0
1999 641,514 107,092 1,039 0.97 628 235 100 72 4 0
2000 647,879 116,930 1,261 1.08 772 287 108 83 8 3
2001 651,034 121,906 994 0.82 615 215 79 78 5 2
Ohio 1997 907,805 74,456 12,342 16.58 6,764 2,766 1,386 1,255 150 21
1998 896,793 75,584 11,773 15.58 6,660 2,654 1,312 1,021 111 15
1999 893,169 103,825 9,254 8.91 5,366 2,101 974 735 70 8
2000 911,072 94,043 7,274 7.73 4,093 1,682 800 633 58 8
2001 911,807 101,144 6,549 6.47 3,848 1,438 649 536 67 11
Oklahoma 1997 275,375 9,184 341 3.71 232 57 20 31 1 0
1998 276,764 7,550 164 2.17 107 28 16 10 3 0
1999 278,461 8,634 127 1.47 81 20 8 17 1 0
2000 283,208 9,499 154 1.62 103 36 9 6 0 0
2001 283,596 11,847 147 1.24 89 33 11 13 1 0
Oregon 1997** 257,876 2,102 80 3.81 51 11 10 7 1 0
1998** 261,090 2,619 97 3.70 57 23 10 7 0 0
1999** 263,482 1,366 108 7.91 70 25 9 3 1 0
2000** 268,083 475 104 21.89 69 19 5 9 0 2
2001** 269,102 971 94 9.68 56 20 10 7 0 1
Pennsylvania 1997 895,951 39,200 9,644 24.60 4,111 2,840 1,421 1,139 112 21
1998 877,252 49,570 9,971 20.11 5,119 2,573 1,164 1,019 80 16
1999 864,659 63,973 6,877 10.75 3,497 1,831 778 699 64 8
2000 884,030 72,272 7,344 10.16 3,833 1,868 826 750 64 3
2001 884,426 45,738 4,259 9.31 2,350 989 420 434 63 3
Rhode Island 1997 77,157 33,826 3,119 9.22 1,779 703 331 272 31 3
1998 75,134 31,866 2,465 7.74 1,522 510 212 200 20 1
1999 75,194 33,229 2,363 7.11 1,465 488 193 191 23 3
2000 77,648 31,332 1,987 6.34 1,235 404 159 166 21 2
2001 77,859 34,765 2,026 5.83 1,267 402 178 166 11 2
Note: State data and analysis may vary from CDC data because of strict CDC guidelines and criteria.
* Confirmed by either one elevated venous test or two elevated capillary tests <12 weeks apart.
† BLL group may be underreported. Certain states do not report BLLs 10–24 µg/dL (see Table 2).
§ Data unavailable for analysis or state surveillance system not in place.
¶ Statewide surveillance start-up year.
** CDC does not have complete dataset.
†† Detailed census data were not available. Differences in 2001 total population estimates are due to rounding.
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South Carolina 1997 309,371 13,310 684 5.14 436 151 57 37 3 0
1998 305,425 9,305 457 4.91 292 92 46 25 2 0
1999 304,583 26,429 548 2.07 386 111 31 19 1 0
2000 318,543 33,527 680 2.03 439 157 38 45 1 0
2001 319,537 46,018 566 1.23 377 122 37 27 2 1
Tennessee 1997 — — — — — — — — — —
1998 — — — — — — — — — —
1999 — — — — — — — — — —
2000 — — — — — — — — — —
2001¶ 452,712 27,912 258 0.92 156 56 27 15 3 1
Texas 1997** 1,928,518 1,286 50 3.89 36 9 3 0 2 0
1998** 1,950,129 876 24 2.74 15 5 3 1 0 0
1999** 1,963,136 937 61 6.51 16 8 18 17 1 1
2000** 1,948,297 11,883 352 2.96 160 92 45 50 4 1
2001 1,960,424 172,373 1,740 1.01 1,069 346 158 151 12 4
Utah 1997 235,849 1,794 44 2.45 19 15 4 6 0 0
1998 243,453 2,492 53 2.13 33 15 3 2 0 0
1999 249,309 2,609 19 0.73 13 3 2 1 0 0
2000 248,430 3,581 22 0.61 12 8 1 1 0 0
2001 249,696 3,433 19 0.55 9 5 2 3 0 0
Vermont 1997 41,322 6,742 306 4.54 186 74 23 22 1 0
1998 39,917 6,253 239 3.82 143 51 26 14 5 0
1999 39,042 6,179 170 2.75 94 37 24 15 0 0
2000 41,709 6,424 178 2.77 105 48 11 13 1 0
2001 41,780 6,455 144 2.23 74 43 17 8 2 0
Virginia 1997 542,983 12,870 864 6.71 413 225 114 103 6 3
1998 542,156 23,781 939 3.95 478 239 111 86 24 1
1999 542,731 24,270 498 2.05 263 143 58 29 5 0
2000 557,736 25,728 614 2.39 367 141 47 57 2 0
2001 560,065 39,291 456 1.16 233 110 53 49 11 0
Washington 1997 466,597 3,712 36 0.97 20 4 5 7 0 0
1998 469,215 3,277 39 1.19 25 7 2 5 0 0
1999 469,925 3,114 28 0.90 16 3 4 4 1 0
2000 475,456 3,616 40 1.11 19 4 9 6 1 1
2001 477,458 3,487 32 0.92 19 4 3 5 1 0
West Virginia 1997 126,536 11,645 267 2.29 172 54 23 15 3 0
1998 124,234 10,473 237 2.26 150 56 18 12 1 0
1999 122,311 9,538 169 1.77 113 36 13 6 1 0
2000 122,919 11,718 173 1.48 115 36 12 9 0 1
2001 122,793 12,159 147 1.21 89 33 15 9 1 0
Wisconsin 1997 405,409 68,620 7,032 10.25 3,688 1,803 784 679 65 13
1998 403,252 69,758 5,347 7.67 2,978 1,305 532 481 44 7
1999 401,769 70,874 4,577 6.46 2,586 1,135 419 397 36 4
2000 414,337 70,578 3,911 5.54 2,323 811 388 351 28 10
2001 415,154 79,467 3,658 4.60 2,162 823 341 294 33 5
Note: State data and analysis may vary from CDC data because of strict CDC guidelines and criteria.
* Confirmed by either one elevated venous test or two elevated capillary tests <12 weeks apart.
† BLL group may be underreported. Certain states do not report BLLs 10–24 µg/dL (see Table 2).
§ Data unavailable for analysis or state surveillance system not in place.
¶ Statewide surveillance start-up year.
** CDC does not have complete dataset.
†† Detailed census data were not available. Differences in 2001 total population estimates are due to rounding.
TABLE 6. (Continued) Children aged <72 months for whom blood lead surveillance data were reported to CDC and number of
children confirmed to have blood lead levels (BLLs) >10 µg/dL by state, year and BLL group — selected U.S. sites, 1997–2001
No. aged Total Confirmed
<72 mos no. with BLLs
for states confirmed* >10 µg/dL No. with confirmed BLLs >10 µg/dL by their
submitting BLLs among highest BLL (µg/dL) at or after confirmation
State Year data No. tested >10 µg/dL tested (%) 10–14† 15–19†  20–24† 25–44 45–69 >70
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TABLE 6. (Continued) Children aged <72 months for whom blood lead surveillance data were reported to CDC and number of
children confirmed to have blood lead levels (BLLs) >10 µg/dL by state, year and BLL group — selected U.S. sites, 1997–2001
No. aged Total Confirmed
<72 mos no. with BLLs
for states confirmed* >10 µg/dL No. with confirmed BLLs >10 µg/dL by their
submitting BLLs among highest BLL (µg/dL) at or after confirmation
State Year data No. tested >10 µg/dL tested (%) 10–14† 15–19†  20–24† 25–44 45–69 >70
Wyoming 1997 37,566 640 11 1.72 6 1 2 2 0 0
1998 37,098 850 15 1.76 6 4 2 3 0 0
1999 36,674 1,240 6 0.48 5 0 0 1 0 0
2000 37,226 1,192 3 0.25 2 0 0 0 0 1
2001 37,226 1,275 4 0.31 3 0 1 0 0 0
U.S. Total 1997 19,872,914 1,703,356 130,512 7.66 72,816 29,684 14,205 12,351 1,247 209
1998 20,893,626 1,736,908 116,532 6.71 67,446 26,027 11,711 10,107 1,084 157
1999 21,237,717 1,809,541 93,235 5.15 54,739 20,546 9,102 7,914 826 108
2000 21,824,399 2,135,932 87,557 4.10 51,722 18,693 8,419 7,749 825 149
2001 22,354,501†† 2,422,298 74,887 3.09 44,730 15,943 6,872 6,464 760 118
Note: State data and analysis may vary from CDC data because of strict CDC guidelines and criteria.
* Confirmed by either one elevated venous test or two elevated capillary tests <12 weeks apart.
† BLL group may be underreported. Certain states do not report BLLs 10–24 µg/dL (see Table 2).
§ Data unavailable for analysis or state surveillance system not in place.
¶ Statewide surveillance start-up year.
** CDC does not have complete dataset.
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